

AP5
DIALOG
Search
9/18/98
VSP

(FILE 'USPAT' ENTERED AT 07:34:29 ON 26 AUG 1998)

L1 199 S 0157
L2 80 S 0157(W)H7 OR 0157:H7 OR 0157?
L3 277 S 0157?
L4 300 S L1-L3
L5 9 S L4 (3P) VACCIN?
L6 21 S L4 AND COLI AND VACCIN?
L7 13 S L6 NOT L5

=> d cit ab l5 -19

9 ANSWERS ARE AVAILABLE. SPECIFIED ANSWER NUMBER EXCEEDS ANSWER SET
SIZE
ENTER ANSWER NUMBER OR RANGE (1):1-9

1. 5,798,260, Aug. 25, 1998, Escherichia coli O157:H7 epithelial
adhesin; Phillip I. Tarr, et al., 435/252.3, 320.1; 536/23.7 [IMAGE
AVAILABLE]

US PAT NO: 5,798,260 [IMAGE AVAILABLE] L5: 1 of 9

ABSTRACT:

A continuous segment of chromosomal DNA from E. coli O157:H7, isolated
on plasmid pSC(overlap) (ATCC No. 69648), encodes an adhesin (SEQ ID
NO:4) that mediates bacterial colonization of bovine intestines.

2. 5,747,293, May 5, 1998, Intimin-like proteins of E. coli; Gordon
Dougan, et al., 530/402, 350, 825 [IMAGE AVAILABLE]

US PAT NO: 5,747,293 [IMAGE AVAILABLE] L5: 2 of 9

ABSTRACT:

The invention is related to antibodies, particularly monoclonal
antibodies, which recognize particularly epitopes of the intimin protein
of enteropathogenic E. coli and enterohemorrhagic E. coli, methods of
detecting such E. coli by use of these antibodies, and kits containing
these antibodies for diagnosis.

3. 5,730,989, Mar. 24, 1998, Oral vaccine against gram negative
bacterial infection; D. Craig Wright, 424/241.1, 197.11, 249.1, 255.1,
258.1, 261.1, 450 [IMAGE AVAILABLE]

US PAT NO: 5,730,989 [IMAGE AVAILABLE] L5: 3 of 9

ABSTRACT:

The present invention concerns an oral preparation useful as an
immunizing agent or vaccine against gram negative bacterial infection.
This oral preparation can also be used as a treatment for those infected
with gram negative bacteria. The preparations can be used against any gram
negative bacterial infection, including Escherichia coli, Shigella
flexneri 2a, and Salmonella enteritidis.

4. 5,654,417, Aug. 5, 1997, Nucleic acid probes for detecting E. coli
O157:H7; Phillip I. Tarr, et al., 536/24.32; 435/6; 536/23.1, 24.3 [IMAGE
AVAILABLE]

5,730,989
*

APS
DIALOG
search
9/98

(FILE 'USPAT' ENTERED AT 10:45:01 ON 18 SEP 1998)

E INTIMAIN
E INTIMIN
L1 3 S E3 OR E7
E INVASIN
L2 17 S E3-E5
L3 18 S L1 OR L2
L4 9 S L3 (2P) (ANTIBOD? OR POLYCLONAL? OR MONOCLONAL OR MONO-C
LON

=> d hit 1-9

✓ US PAT NO: 5,800,821 [IMAGE AVAILABLE]

L4: 1 of 9

Nystrom
EA.

DRAWING DESC:

DRWD(2)

FIG. 1 is a graph showing SLT-I B subunit expression in *B. subtilis* using the SPAC promoter (pDA1) or glutamine synthetase promoter (pDA6) with and without added glutamine in the culture medium (L. broth). The B subunit in culture supernatants was measured by ELISA using a B subunit specific **monoclonal antibody** as the capture molecule, and is given as absorbance units. Cultures reached stationary phase at 4-5 hours.

DRAWING DESC:

DRWD(3)

FIG. 2 is a blot showing a HEp-2 cell binding assay in parental (negative control) *E. coli* (Lane A), *E. coli* expressing DppE-Inv192 fusion protein (Lane B) and *E. coli* expressing the whole **Invasin** molecule (positive control) in Lane C.

DRAWING DESC:

DRWD(4)

FIG. 3 is a bar graph showing results when whole cells or spheroplasts were incubated with iodinated **monoclonal antibody** 3A2-1 directed toward the C-terminus of **Invasin**. Bound counts were determined following washing.

DRAWING DESC:

DRWD(5)

FIG. 4 is a Western blot of DppE-Inv192 expression in *B. subtilis* parental cells (lane B), recombinant spheroplast cytoplasm (lane C), recombinant spheroplast membranes (lane D), whole recombinant spheroplasts (lane E), and whole recombinant cells (lane F). **Invasin** expression in *E. coli* (positive control) is shown in lane A.

DRAWING DESC:

DRWD(6)

FIG. 5 is a graph showing whole cells from *E. coli* (with or without a plasmid coding for **Invasin**) or *B. subtilis* HJS31 (Inv -) and recombinant *B. subtilis* (CwbA-Inv192 +) incubated with iodinated 3A2-1. The total counts bound following washes are shown.

DRAWING DESC:

DRWD(7)

FIG. 6 is a graph showing binding of murine **antibodies** to **Invasin** in an ELISA from 15 mice orally immunized with spores whose vegetative cells expressed CwbA-Inv fusion proteins. The results are expressed as absorbance units (405 nm).

DETDESC:

DETD(23)

There are several ways to determine where the expressed fusion proteins are situated in the spore coat or cell wall. One way is to determine if radiolabeled **monoclonal antibody** 3A2-1 (which is directed toward the C-terminal 192 amino acids of **Invasin**) is able to bind preferentially to the spores or vegetative cells (as we found with spheroplasts for the DppE-**Invasin** fusion protein, and for whole cells with the CwbA-Inv192 fusion protein). Another is to use indirect or direct fluorescence with either a FITC conjugated anti-murine **antibody** or fluoresceinating 3A2-1, respectively. It may be necessary to use ultrastructural morphological techniques to determine the site of the fusion protein in some cases, e.g., by using immunogold techniques with 3A2-1.

DETDESC:

DETD(24)

We have expressed proteins, such as Shiga-like toxin I B subunit (SLT-I B) and portions of **Invasin** from *Y. pseudotuberculosis*, in *B. subtilis*. We have expressed SLT-I B from both plasmid and chromosomal sites within *B. subtilis* and clearly demonstrated the expressed protein in culture supernatants of the genetically altered *B. subtilis* cells. We have constructed genetic fusions between *B. subtilis* cell membrane or cell wall proteins and the carboxy-terminal domain of **Invasin**, and have expressed the resultant fusion proteins in *B. subtilis*. Our experiments established that it is possible to target a portion of **Invasin** to either the cell membrane or cell wall of *B. subtilis*, and that the fusion protein retains the phenotypic characteristics of **Invasin**, in terms of HEp-2 cell binding. Additionally, we have demonstrated that the CwbA-Inv fusion proteins are immunogenic when expressed from vegetative *B. subtilis* following oral administration of spores encoding the CwbA-Inv fusions.

DETDESC:

DETD(38)

The dppE gene encodes a dipeptide binding protein which is secreted from *B. subtilis* but remains attached to the membrane by a lipoprotein

linkage. We hoped therefore that dppE would be exposed on the cell surface. The C-terminus of the dppE gene was fused in frame to DNA encoding the 192 C-terminal amino acids of **Invasin** from *Yersinia pseudotuberculosis*. This **Invasin** protein is a 103 kDa protein (986 amino acids) which has been shown to be localized in the outer membrane (Isberg et al., Cell, 1987, 50:769-78). The integrin binding domain of **Invasin** has been identified as being within the carboxyl-terminal 192 amino acids (Leong et al., EMBO J., 1990, 9:1979-89). Thus, the C-terminal 192 amino acid portion of **Invasin** has the potential to cause bacterial cells on whose outer surface it is expressed to attach to mammalian cells.

DETDESC:

DETD(39)

To construct the DppE-**Invasin** fusion protein, we cloned the whole of the dppE gene, excluding the termination codon, using PCR. The primers were designed to have EcoRI and KpnI sites upstream, and a SacI site downstream to allow cloning into the EcoRI and SacI sites of pBluescript SK and to facilitate sequencing of the fusion gene. The dppE gene was then cloned as an EcoRI-SacI fragment into the EcoRI and SacI sites of pAF1 (Fouet et al., 1990, supra). The glutamine synthetase promoter was cloned upstream of the dppE gene as an EcoRI-KpnI fragment. The nucleotides encoding the carboxy terminal 192 amino acids of **Invasin** were then amplified using PCR. SacI sites were appended to each end to allow in-frame insertion into the SacI site of the previously constructed plasmid. The result was a plasmid (pDA74) containing a fusion gene consisting of the whole of the dppE coding sequence and the portion of the carboxy terminus of **Invasin** which is responsible for binding to cells. The gene fusion was positioned between the amino and carboxy terminal portions of the amyE gene as before, to allow integration into the *B. subtilis* chromosome.

DETDESC:

DETD(40)

Expression of the DppE-**Invasin** fusion protein was demonstrated in *E. coli*. The fusion protein (approximately 80 kDa) was detected by Western blot using a **monoclonal antibody** (3A2-1) directed toward the C-terminus of **Invasin** (Leong et al., 1991, supra). We determined the ability of the fusion protein expressed in *E. coli* to bind HEP-2 cells by transferring the fusion protein onto nitrocellulose and then incubating the membrane with HEP-2 cells. Bound HEP-2 cells were detected by virtue of their endogenous alkaline phosphatase activity. HEP-2 cells bound to **Invasin** present in the positive control *E. coli* (FIG. 2, Lane C), and to the DppE-Inv192 fusion protein in lane B (FIG. 2). Non-specific binding can be seen in lanes A and B in a band just below the level of the DppE-Inv192 fusion protein (FIG. 2). pDA74 was then linearized and introduced into *B. subtilis*. The fusion protein was not only expressed in *B. subtilis* but was also able to bind HEP-2 cells, as determined by blotting.

DETDESC:

DETD(41)

In order to increase expression of the fusion protein, pDA74 was

introduced into *B. subtilis* strain HJS31 (a *glnR* mutant) in which the glutamine synthetase promoter is expressed constitutively. The physical location of the fusion protein in the *B. subtilis* strain carrying the DppE-Inv192 fusion was determined using a variety of techniques. Binding of ¹²⁵I-labeled **monoclonal anti-Invasin antibody 3A2-1** to the fusion protein was confirmed by an autoradiograph of a Western blot. When binding to whole bacterial cells was tested, the iodinated **antibody** bound to both the parental and the DppE-Inv192 recombinant strain to approximately the same extent (FIG. 3). However, when binding to spheroplasts (prepared by incubating whole cells with lysozyme, and confirmed by microscopy) was determined, there was approximately 5-fold more binding of the **antibody** to the recombinant spheroplasts than to control spheroplasts (FIG. 3).

DETDESC:

DETD(44)

Example 3: Expression of *B. subtilis* Cell Wall Protein-Invasin Fusion

DETDESC:

DETD(45)

B. subtilis produces a number of cell wall proteins. Two of the best studied classes of cell wall proteins are the autolysins and their associated modifier proteins, which are thought to be important in regulating autolysin activity. Kuroda et al. (J. Bacteriol., 1991, 173:7304-12) cloned and sequenced a major autolysin gene, designated *cwlB*. Kuroda et al. (1991, supra) subsequently sequenced a gene for a modifier protein, designated *cwbA*, which is immediately upstream of *cwlB*. We constructed a genetic fusion using the whole of *cwbA* and the DNA encoding the C-terminal 192 amino acids of **Invasin**. The *cwbA* gene encodes a polypeptide of 705 amino acids with a molecular mass of 76,725 Da (Kuroda et al., supra). In order to clone the *cwbA* gene, we designed PCR primers which annealed to the 5' end of the gene and included the ribosomal binding site. The reverse primer was designed to anneal to the downstream portion of the gene and to exclude the termination codon. The upstream primer contained a *KpnI* site and the downstream primer a *SacI* site. Following PCR, we obtained a 2140 bp fragment containing the *cwbA* gene, as expected. Following appropriate restriction digestion, the fragment was inserted into the *KpnI* and *SacI* sites of pBluescript SK. The 5' portion of the insert was sequenced to check that it was the correct gene. The next stage of the construction involved moving the *KpnI*-*SacI* fragment from the pBluescript vector into plasmid pDA74 (described above) which placed the cell wall protein gene under the glutamine synthetase promoter. Next, the DNA encoding the terminal 192 amino acids of **Invasin** was amplified using PCR primers with *SacI* restriction sites on each end. The PCR product was inserted downstream of and in-frame with *cwbA*. The fusion site was sequenced and the final plasmid containing the *cwbA*-inv192 gene fusion was designated pDA84. The gene fusion was integrated into the *amyE* locus of *B. subtilis* HJS31. This strain produced detectable levels of the fusion protein (by Western blot with **monoclonal antibody 3A2-1**). The size of the reactive band was about 100 kDa, as expected.

DETDESC:

DETD(46)

When *B. subtilis* expressing the CwbA-Inv192 fusion protein was grown to early stationary phase and the cells treated with lysozyme in the presence of 0.5M sucrose to maintain the spheroplasts, there was clearly more CwbA-Invasin protein, as a proportion of the total protein, in the lysozymal supernatant than in the spheroplasts. Thus it appeared that the CwbA-Invasin protein was predominantly associated with the cell wall. When we examined the binding of iodinated 3A2-1 to *B. subtilis* HJS31 and the recombinant CwbA-Inv192 expressing *B. subtilis* at three different points in their growth curve, there was a clear difference in the binding of the **monoclonal antibody** to the two strains (FIG. 5). There was a similar difference when the same experiment was performed with *E. coli* which did and did not express Invasin (FIG. 5). The same number of bacterial cells was used at each growth point, and the ratio of binding in overnight cultures between Invasin positive and negative *B. subtilis* (8.1) and *E. coli* (6.0) was similar. There was some suggestion that the binding of 3A2-1 to the Inv(+) *Bacillus* increased as the cultures grew, since the binding to control HJS31 did not really change during the course of the culture.

DETDESC:

DETD(47)

The binding of iodinated **monoclonal antibody** to spheroplasts was then assessed. Whole cells and spheroplasts of *B. subtilis* HJS31 and the recombinant *B. subtilis*, which had been grown to an optical density (600 nm) of approximately 1.0, were incubated with iodinated 3A2-1 and the bound counts compared. As shown in Table 1, the ratio of bound counts between the two strains suggested that removing the cell wall also eliminated most of the preferential binding of 3A2-1.

DETDESC:

DETD(63)

To determine whether or not the otherwise unmodified spores of *B. subtilis* containing the DNA encoding the CwbA-Inv fusion proteins could induce an immune response in vivo, spores were administered orally, directly into the stomachs, of 19 mice using a gavage needle. Each mouse received four doses of 1.times.10.sup.10 spores at 10 day intervals. Animals were bled prior to the experiment (for control serum) and 10 days after the third and fourth inocula. The presence of IgG serum **antibodies** to Invasin was measured using an ELISA format with recombinant Invasin as the capture molecule. Five of the mice developed serum **antibodies** to Invasin with an increasing titer after multiple immunizations (FIG. 6). The **antibodies** detected by ELISA were also functional and able to neutralize Invasin, in that they were able to inhibit invasion by Inv-positive *E. coli* into mammalian HEP-2 cells.

DETDESC:

DETD(64)

We know that the spores themselves do not express the Invasin protein, and therefore the only way these mice could develop an immune response to Invasin is if the spores germinate and express the fusion antigen. In these experiments, we did nothing to optimize colonization

and survival of the vector in the gastrointestinal tract. It is possible that prolonged recycling of spores could occur by coprophagy, typical in mice. However, this would not produce a specific **antibody** response without germination and expression of the protein antigen.

DETDESC:

DETD(65)

The data from Examples 1-5 show that the SLT-I B subunit can be expressed in *B. subtilis* and that this protein is exported from the cell, presumably by virtue of its own signal peptide. These experiments show that it is possible to construct and express two different fusion proteins (using in this case the C-terminus of **Invasin**) directed toward either the cell membrane or the cell wall of *Bacillus*. The experiments also show that *B. subtilis* vegetative cells are able to survive in the GI tract of mice at least two days following oral gavage. This indicates survivability of the cells, one of the requirements of our vaccine constructs. We also demonstrate that spores can be recovered to at least 7 days post-gavage, which is clearly longer than the GI transit time, and our data show that following oral immunization with spores, germination can occur within the gastrointestinal tract and the resulting vegetative cells can express the *inv* fusion gene in sufficient quantities to result in a systemic immune response.

US PAT NO: 5,798,260 [IMAGE AVAILABLE]

L4: 2 of 9

Cute
SUMMARY:

BSUM(12)

Outer membranes of *E. coli* O157:H7 competitively inhibit adherence to HEp-2 cells, an inhibition which is not due to H7 flagellin or O157 lipopolysaccharide (65). Adherence of *E. coli* O157:H7 to HEp-2 cells was reduced, but not abolished, by **antibody** to a 94 kDa outer membrane protein (64). **Antibodies** to enterotoxigenic *E. coli* colonization factor antigens I and II do not detect surface structures on *E. coli* O157:H7 (78). *E. coli* O157:H7 do not have sequences homologous to the EPEC adherence factor plasmid or to the diffuse adherence adhesin (71).

SUMMARY:

BSUM(13)

Some investigators have suggested that the epithelial cell adhesin of *E. coli* O157:H7 is encoded by its *eae* gene (17). *E. coli* O157:H7 *eae* is related to *inv*, which encodes *Yersinia* **invasin**, which also functions as an adhesin, and EPEC *eae*, which encodes **intimin**. An *eae* deletion mutant of *E. coli* O157:H7 neither adhered to HEp-2 cells nor caused the attaching and effacing (AE) lesion in newborn pigs (17). When deletion mutants were complemented in trans by an intact *eae* gene, the strain could again cause the AE lesion, but still could not adhere in vitro. However, data from other groups suggest that the *eae* gene product is not an adhesin for *E. coli* O157:H7. First, despite sequence homology to *inv* in its bacterial localization and transmembrane domains, the receptor binding domain of *E. coli* O157:H7 *eae* is quite dissimilar (4,82). Second, an *eae* insertional mutant in *E. coli* O157:H7 retained the ability to adhere to HEp-2 cells in a quantitative adherence assay (41). Third, an *eae* gene product does not confer adherence on nonadherent laboratory

strains of E. coli. (Jerse, A., et al., Proc. Natl. Acad. Sci. USA 87:7839-7843, 1990) Thus, a molecule other than the eae gene product in E. coli O157:H7 appears to be the primary adhesin of E. coli O157:H7 for bovine epithelial cells, enabling this human pathogen to colonize the bovine gastrointestinal tract.

SUMMARY:

BSUM(14)

Bacterial adhesins, when used as immunogens, prevent disease or colonization of mucosal sure by bacteria in many animals (1,18,21,29,30,36,49,50,55,61,68,81, which are hereby incorporated by reference). The reduction of E. coli O157:H7 at its bovine source would enhance the microbiologic safety of food derived from cattle, and lessen the environmental biohazard risk posed by the approximately 100,000 cattle detectably infected with E. coli O157:H7 at any one time in the United States. The availability of **antibody** for passive immunization would greatly mitigate the harm engendered by outbreaks of this infection.

US PAT NO: 5,759,551 [IMAGE AVAILABLE]

L4: 3 of 9

SUMMARY:

BSUM(13)

Moreover, protein linkage to LHRH is problematic because the majority of immune responses are directed to the carrier rather than to LHRH (the mass of the toxin molecule(s) is much greater than that of LHRH). This phenomenon leads to carrier-induced immune suppression. Because the majority of cancer or endometriosis patients have been previously immunized with diphtheria and tetanus vaccines as part of mandatory immunization programs, **antibody** and/or suppressor T cell responses directed to tetanus or diphtheria toxin components of the vaccines can interfere with the subsequent immune responses to toxin-linked LHRH immunogens.

SUMMARY:

BSUM(14)

Accordingly, an immune enhancer that is suitable for human use, inexpensive and capable of stimulating an early and strong immune response to LHRH has been sought. Likewise this immune enhancer should avoid carrier-induced suppression. Hence, it has been found that peptides containing particular structural arrangements of a Th epitope alone or linked to an **invasin** domain (as an immune enhancer) and LHRH (as immunogen) are effective in stimulating the production of **antibodies** against LHRH.

SUMMARY:

BSUM(15)

The present invention relates to peptides, preferably synthetic peptides, which are capable of inducing **antibodies** against LHRH that lead to the suppression of LHRH levels in males or females. The subject peptides are useful for inducing infertility and for treating prostatic

hyperplasia, androgen-dependent carcinoma, prostatic carcinoma, testicular carcinoma, endometriosis, benign uterine tumors, recurrent functional ovarian cysts (severe) premenstrual syndrome or for prevention or treating estrogen-dependent breast cancer. In particular, peptides of this invention have a Th epitope and carboxyl-terminal LHRH, or a peptide analog of LHRH. These peptides are effective as immunogens and therapeutics. The peptides of this invention are capable of reducing serum testosterone to levels comparable to those obtained by orchiectomy (castration) and of causing reversible atrophy of the testes, prostate and other androgen- or estrogen-dependent sex organs. Optionally, the peptides have an **invasin** domain as an immune stimulator.

SUMMARY:

BSUM(17)

A further aspect of the invention relates to a method for suppressing activity of circulating LHRH levels in a mammal by administering one or more of the subject peptides to the mammal for a time and under conditions sufficient to induce functional **antibodies** directed against said LHRH. Suppression of LHRH activity is useful to treat prostatic hyperplasia, androgen-dependent carcinoma, prostatic carcinoma, testicular carcinoma, endometriosis, benign uterine tumors, recurrent functional ovarian cysts or (severe) premenstrual syndrome, or to prevent or treat estrogen-dependent breast cancer. More particularly, the invention provides a method for inducing infertility in a mammal by administering the subject vaccine compositions to the mammal for a time and under conditions to produce an infertile state in the mammal. Similarly, this invention relates to a method for treating androgen-dependent carcinoma by administering the subject vaccine compositions to the mammal for a time and under conditions to effect regression or prevent growth of the carcinoma.

SUMMARY:

BSUM(18)

Yet another aspect of the invention relates to an immunogenic synthetic peptide of about 30 to about 90 amino acids which contains an immunostimulatory **invasin** domain, a helper T cell (Th) epitope and a peptide hapten. These three elements of the peptide can be covalently joined in any order provided that either the immunoreactivity of the peptide hapten is substantially preserved or that immunoreactivity to a self-peptide can be generated. The peptide haptens of the invention include self-peptides LHRH, amylin, gastrin (gastrin.sub.34 and gastrin.sub.17), gastrin releasing peptide and a peptide derived from the CH4 domain of the IgE molecule as well as peptides from Chlamydia trachomatis, human immunodeficiency virus, Plasmodium berghei, or any other B cell epitope (such as from pathogenic organisms) or a CTL (cytotoxic T cell)-generating epitope. Further these peptides have one or more amino terminal (A).sub.n groups, where A is an amino acid, a-NH.sub.2, tripalmitoyl cysteine or a fatty acid and n is from 1 to about 10. The three elements of the subject peptides can be separated by a (B).sub.o spacer group, where B is independently any amino acid and o is from 0 to about 10.

DRAWING DESC:

DRWD(30)

FIG. 30 graphically depicts levels of anti-LHRH specific **antibody** produced in rats following immunization with Inv: HBsAgT.sub.h : LHRH (peptide 32). Peptide 32 consists of a segment of Yersenia adhesion molecule, **Invasin**, linked to a T cell helper epitope derived from the hepatitis B virus surface antigen linked to LHRH. Five sexually mature Sprague-Dawley male rats per group were given peptide 32 equivalent to 100 .mu.g of peptide A by subcutaneous administration. The antigen was formulated on aluminum hydroxide and given at week 0, 3 and 6. The control group was given unmodified LHRH on alum using the same immunization schedule.

DETDESC:

DETD(8)

5. Covalent Addition of an **Invasin** Domain as an Adjuvant. The **invasins** of the pathogenic bacteria Yersinia spp. are outer membrane proteins which mediate entry of the bacteria into mammalian cells (Isberg and Leong, 1990, Cell 60:861). Invasion of cultured mammalian cells by the bacterium was demonstrated to require interaction between the Yersinia **invasin** molecule and several species of the .beta.1 family of integrins present on the cultured cells (Tran Van Nhieu and Isberg, 1991, J. Biol. Chem. 266:24367). Since T lymphocytes are rich in .beta.1 integrins (especially activated immune or memory T cells) the effects of **invasin** upon human T cell have been investigated (Brett et al., 1993, Eur. J. Immunol. 23:1608). It is thought that integrins facilitate the migration of immune T cells out of the blood vessels and through connective tissues to sites of antigenic challenge through their interaction with extracellular matrix proteins including fibronectin, laminin and collagen. The carboxy-terminus of the **invasin** molecule was found to be costimulatory for naive human CD.sup.4 +T cells in the presence of the non-specific mitogen, anti-CD3 **antibody**, causing marked proliferation and expression of cytokines. The specific **invasin** domain which interacts with the .beta.1 integrins to cause this stimulation also was identified (Brett et al., 1993). Because of the demonstrated T cell co-stimulatory properties associated with this domain, it can be linked it to promiscuous T.sub.h epitope: LHRH constructs.

DETDESC:

DETD(10)

7. Selection of an Adjuvant/Emulsion Formulation to Maximize **Antibody** Responses. In addition to the significant adjuvanting properties associated with covalent modifications of the T.sub.h epitope: LHRH constructs (e.g the **invasin** domain and/or Pam.sub.3 Cys), addition of exogenous adjuvant/emulsion formulations which maximize immune responses to the LHRH immunotherapeutic immunogens have been investigated. The adjuvants and carriers that have been evaluated are those: (1) which have been successfully used in Phase I human trials; (2) based upon their lack of reactogenicity in preclinical safety studies, have the potential for approval for use in humans; or (3) have been approved for use in food and companion animals.

DETDESC:

DETD(247)

Further Modification of the LHRH Immunogens to Amplify **Antibody**
Induction: Addition of an **Invasin** Domain

DETDESC:

DETD(248)

T cell activation can also be brought about by LHRH that is covalently linked to a specific fragment from the **invasin** protein of the pathogenic bacteria *Yersinia* spp. Peptide 32, in which a domain of the **invasin** protein is linked to the HBs T.sub.h epitope: LHRH construct (i.e. Inv.sub.718-732 +peptide 18) has been synthesized. Peptide 32 is organized in five linear domains, from the amino- to the carboxyl-terminus, as follows: the **invasin** T cell stimulator (Inv), a glycine spacer (GG), the hepatitis B surface antigen helper T cell epitope (HBsAg T.sub.h 1), a glycine spacer (GG), and LHRH. Peptide 32 is thus represented as: Inv: GG: HBsAg T.sub.h 1: GG: LHRH. The following provides a specific example of the significant efficacy imparted to the LHRH immunogen by the addition of the **invasin** domain. The experimental design is the same as in Example 5 except as indicated otherwise. Experimental Design:

DETDESC:

DETD(256)

FIG. 30 describes the LHRH-specific **antibody** titers produced in rats immunized with peptide 32. Significant titers were achieved after the first booster immunization (at 3 weeks) which continued to increase following the second booster immunization at 6 weeks. By week 8, 4 of 5 animals exhibited LHRH **antibody** titers above 2 nmole/L. Control animals immunized with an Inv.sub.718-732 : LHRH construct, lacking a T.sub.h epitope, did not produce any measurable LHRH-specific **antibody**. Serum testosterone levels (FIG. 31) fell precipitously in the animals responding to peptide 32, and by week 8, testosterone levels were below the threshold for castration. Serum testosterone in these animals remained unmeasurable for the remainder of the experiment. As demonstrated by FIG. 32, dramatic organ atrophy was achieved in the four responding animals. The testes of control animals immunized with peptide 18 (HBs T.sub.h : GG: LHRH; lacking the **invasin** epitope) were unaffected at the end of this experiment (i.e. at week 10). This result is especially important since the **invasin**-containing LHRH peptide was formulated on alum and administered subcutaneously. Previous studies with LHRH linked to high molecular weight carrier molecules, e.g. tetanus and diphtheria toxins, required formulation with Freund's complete adjuvant or other reactogenic adjuvants to achieve any significant degree of efficacy.

DETDESC:

DETD(258)

1. The **invasin** fragment provides a significant improvement in the immune responses to T.sub.h : LHRH constructs.

DETDESC:

DETD(262)

An experiment testing the efficacy of the cocktail of immunogens as described in Examples 10 and 11, was conducted except that the HBs T.sub.h : GG: LHRH construct was replaced with peptide 32. The protocol for this example is identical to that used in Example 11. As above, animals received 100 .mu.g of peptide on alum, administered at 0, 3 & 6 weeks. As demonstrated by FIG. 33, rapid and potent anti-LHRH **antibody** responses were produced in response to immunization with the **Invasin** fragment-containing cocktail when formulated on alum. By 8 weeks, 6 of 6 animals receiving the peptide 32-containing cocktail expressed serum testosterone levels (FIG. 34) below the castration threshold (i.e. less than 0.5 nmole/L). In contrast, 4 of 6 animals receiving an equivalent dose of peptide 32 alone on alum had castration levels of testosterone. These data suggest that any genetic variability associated with responses to the **invasin** fragment are overcome by its presentation in the cocktail containing the different T.sub.h constructs. FIG. 35 describes the testis weights at the end of the experiment (at 10 weeks). Five of 5 animals receiving the peptide 32-containing cocktail of immunogens exhibited significant organ atrophy and by histological examination were functionally sterile.

DETDESC:

DETD(263)

Invasin.sub.718-732 linked to: HBs T.sub.h :GG:LHRH generates peptide 32, to MV.sub.F1 T.sub.h :GG:LHRH generates peptide 33, to PT.sub.2 T.sub.h :GG:LHRH generates peptide 34, to TT.sub.1 T.sub.h :GG:LHRH generates peptide 35, to TT.sub.4 T.sub.h :GG:LHRH generates peptide 36, and to TT.sub.5 T.sub.h :GG:LHRH generates peptide 37. Experiments designed to evaluate the efficacy of peptides 32-37, alone and in combination, are conducted in accordance with this and Example 13.

(orle) /
US PAT NO: 5,747,293 [IMAGE AVAILABLE]

L4: 4 of 9

ABSTRACT:

The invention is related to **antibodies**, particularly **monoclonal antibodies**, which recognize particularly epitopes of the **intimin** protein of enteropathogenic E. coli and enterohemorrhagic E. coli, methods of detecting such E. coli by use of these **antibodies**, and kits containing these **antibodies** for diagnosis.

SUMMARY:

BSUM(1)

The present invention relates to **antibodies**, particularly **monoclonal antibodies** which recognise particular epitopes of the **intimin** protein of enteropathogenic E. coli and enterohemorrhagic E. coli, their use in the detection of such enteropathogenic E. coli, and kits containing such **antibody** for such use.

SUMMARY:

BSUM(10)

We have now generated further fusion proteins in addition to MEP-Int.sub.EPEC280 (amino acids 660-939). These fusion proteins include different amino acid sequences derived from the 280 binding domain.

MBP-Int.sub.EPEC150 (amino acids 790-939) was found to be the smallest fusion protein that had the ability to mediate cell binding. In addition the cysteine residue at position 937 of Int seems to be required for binding activity, as substitution with serine results in a loss in biological activity. Using the MBP expression system we have obtained high yields of MBPInt.sub.EPEC280, MBP-Int.sub.EHEC275, MBP-Int.sub.CF280 and MBP-Inv.sub.YP280 fusion proteins. These proteins can be used to immunise mice in order to generate specific **monoclonal antibodies**. We have now identified **monoclonal antibodies** which specifically recognise the antigen MBP-Int.sub.EPEC280 and which do not recognise MBP, MBP-Int.sub.EHEC275, MBP-Int.sub.CF280 or MBP-Inv.sub.YP280. These **antibodies** are therefore specific for the 280 amino acid domain of Int.sub.EPEC and will therefore be useful in both the detection and/or treatment of EPEC infection.

SUMMARY:

BSUM(11)

Similarly, MBP-Int.sub.EHEC275 can be used to generate **monoclonal antibodies** which recognise MBP-Int.sub.EHEC275 but not MBP-Int.sub.EPEC280.

SUMMARY:

BSUM(12)

Thus, in a first aspect, the present invention provides an **antibody** which recognises a region within either the carboxy-terminus 280 amino acid domain of the enteropathogenic E. coli **intimin** protein (Int.sub.EPEC280) or the enterohemorrhagic E. coli **intimin** protein (Int.sub.EPEC 280).

SUMMARY:

BSUM(13)

In the context of the present invention, "**antibody**" refers to conventional **polyclonal** and **monoclonal antibodies** and includes antigen binding portions or fragments thereof, e.g. Fab and/or fragments of Fab.

SUMMARY:

BSUM(14)

In a preferred embodiment, the **antibody** is a **monoclonal antibody**. In particularly preferred embodiments, the **antibody** is a **monoclonal antibody** which recognises a region within the following carboxy-terminus 280 amino acid sequence:

SUMMARY:

BSUM(19)

Preferably, a **monoclonal antibody** recognising Int.sub.EPEC280 does not recognise the carboxy-terminus 280 amino acid domain of the **intimin** protein from enterohemorrhagic E. coli (Int.sub.EHEC 275) or *Citrobacter freundii* biotype 4280 (Int.sub.CF 200) or the

carboxy-terminus 280 amino acid domain of the invasion protein from *Yersinia pseudotuberculosis* (Inv.sub.YP 200)

SUMMARY:

BSUM(20)

More preferably, the **monoclonal antibody** recognising Int.sub.EPEC280 recognises an epitope in the 660-790 amino acid region of the enteropathogenic *E. coli* **intimin** protein.

SUMMARY:

BSUM(21)

Hybridomas producing **monoclonal antibodies** of the invention are also included within the scope of the invention.

SUMMARY:

BSUM(22)

The properties of the **monoclonal antibodies** of the invention render them useful for detecting enteropathogenic *E. coli* and enterohemorrhagic *E. coli*. Thus, the invention also provides the use of such **monoclonal antibodies** in detecting enteropathogenic and enterohemorrhagic *E. coli*.

DETDESC:

DETD(44)

The repertoire of MBP-Int.sub.EPEC fusion proteins was used in an ELISA assay to identify the region within the 280 domain that was recognised by the **monoclonal antibodies**. MBP, MBP-Int.sub.EHEC275, MBP-Int.sub.CF280 and MBP-Inv.sub.YP280 were used as controls.

DETDESC:

DETD(46)

Two productive hybridomas secreting specific anti Int.sub.EPEC280 **monoclonal antibodies** were cloned. Using an ELISA based assay we found that both **monoclonal antibodies** reacted with Int.sub.EPEC280 but not with MBP, MBP-Int.sub.EHEC275, MBP-Int.sub.CF280 and MBP-Inv.sub.YP280. In order to identify the region within the 280 domain that contain the specific epitopes, the **monoclonal antibodies** were tested against a collection of different MBP-Int.sub.EPEC fusion proteins that included in addition to MBP-Int.sub.EPEC280 (amino acids 660-939) also MBP-Int.sub.EPEC150 (amino acids 790-939), MBP-Int.sub.EPEC120C (amino acids 820-939), MBP-Int.sub.EPEC120N (amino acids 790-909), MBP-Int.sub.EPEC 70 (amino acids 870-939): MBP-Int.sub.EPEC40 (amino acids 820-859) and MBP-Int.sub.EPEC280CS (as Int.sub.EPEC280, but with Cys to Ser substitution at position 937). Both **monoclonal antibodies** recognised the 280 domain acids domain of Int.sub.EPEC but failed to react with any of the other derivatives of Int.sub.EPEC. We concluded that both **monoclonal antibodies** recognised an epitope that mapped between amino acids 660-790 of Int. Preliminary results from

agglutination assays and ELISA-based tests performed with both **monoclonal antibodies**, indicated that they can detect expression of **intimin** at the surface of several serotypes of EPEC but cannot react with eaeA mutant strain of EPEC (CVD206) or with *Citrobacter freundii* biotype 4280.

US PAT NO: 5,702,727 [IMAGE AVAILABLE]

L4: 5 of 9

SUMMARY:

BSUM(21)

Exemplary adhesion molecules include **invasin** proteins of certain pathogenic bacteria, such as *Yersinia*, *Shigella*, and *Salmonella*. Suitable **invasins** are encoded by the ail gene families of each of these species, as described in Leong et al. (1991) *Infect. Immun.* 59:3424-3433, the disclosure of which is incorporated herein by reference.

SUMMARY:

BSUM(22)

In addition to **invasins**, a suitable binding moiety may be, for example, a mono- or **polyclonal antibody** or fragment thereof, an **IgA antibody** or fragment thereof, a viral capsid, a capsid of adenovirus, cholera toxin B subunit, transferrin or a fragment thereof, lactoferrin or a fragment thereof, vitamin D, EGF or a fragment thereof, *Pseudomonas* exotoxin, diphtheria toxin, and the like.

SUMMARY:

BSUM(24)

Particularly preferred binding moieties will contain the tripeptide arginine-glycine-aspartic acid (RGD) or the pentapeptide glutamic acid-isoleucine-leucine-aspartic acid-valine (EILDV) within their binding recognition site. The RGD tripeptide is widely conserved among many adhesive proteins present in extracellular matrices as well as being part of at least most **invasin** proteins. The RGD peptide may be utilized by itself and bound to the drug carrier particle, as described in more detail hereinbelow, or it may be obtained or synthesized as part of a larger oligopeptide which is bound to the drug carrier particle. RGD peptide is commercially available from GIBCO BRL Life Technologies, Inc. (Gaithersburg, Md.) and as Peptide-2000.TM. from Telios. Additional preferred binding moieties are the peptides arginine-glycine-aspartic acid-valine (RGDV), arginine-glycine-aspartic acid-serine (RGDS), arginine-glycine-aspartic acid-phenylalanine (RGDF), and glycine-arginine-glycine-aspartic acid-threonine-proline (GRGDTP).

SUMMARY:

BSUM(25)

It will be appreciated that the binding moiety may comprise a variety of other molecular structures, including **antibodies**, lectins, nucleic acids, and other receptor ligands, and fragments thereof. Once a desired target molecule is known, such as the integrins identified above, it will be possible to prepare or synthesize other molecules which are capable of binding the target with the requisite affinity or avidity. For example,

antibodies, including both **polyclonal** and **monoclonal antibodies**, may be raised against the integrin or other target molecule using conventional techniques, as described in Harlow and Lane, eds., **Antibodies: A Laboratory Manual**, Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y. (1988), the disclosure of which is incorporated herein by reference.

CLAIMS:

CLMS(5)

5. A method as in claim 1, wherein the binding moiety is selected from the group consisting of an oligopeptide containing the sequence RGD, an **invasin** molecule or a fragment thereof, EGF or a fragment thereof, and an **antibody** or a fragment thereof.

US PAT NO: 5,681,736 [IMAGE AVAILABLE]

L4: 6 of 9

SUMMARY:

BSUM(32)

Ipa proteins are logical vaccine candidates although their protective efficacy has not been clearly established. Ipa B and Ipa C are immunodominant proteins (Hale, et al., Infect. Immun., 50:620-629, 1985). Furthermore, the 62 kDa Ipa B protein (the **invasin** that initiates cell entry and functions in the lysis of the membrane-bound phagocytic vacuole) (High, et al., EMBO J., 11:1991-1999, 1992) is highly conserved among Shigella species. The prolonged illness observed in malnourished children who have no significant mucosal **antibody** to Shigella Ipa suggests that the presence of mucosal **antibody** to Ipa may limit the spread and severity of infection.

US PAT NO: 5,679,564 [IMAGE AVAILABLE]

L4: 7 of 9

SUMMARY:

BSUM(32)

Ipa proteins are logical vaccine candidates although their protective efficacy has not been clearly established. Ipa B and Ipa C are immunodominant proteins (Hale, et al., Infect. Immun., 50:620-629, 1985). Furthermore, the 62 kDa Ipa B protein (the **invasin** that initiates cell entry and functions in the lysis of the membrane-bound phagocytic vacuole) (High, et al., EMBO J., 11:1991-1999, 1992) is highly conserved among Shigella species. The prolonged illness observed in malnourished children who have no significant mucosal **antibody** to Shigella Ipa suggests that the presence of mucosal **antibody** to Ipa may limit the spread and severity of infection.

US PAT NO: 5,620,708 [IMAGE AVAILABLE]

L4: 8 of 9

SUMMARY:

BSUM(21)

Exemplary adhesion molecules include **invasin** proteins of certain pathogenic bacteria, such as Yersinia, Shigella, and Salmonella. Suitable **invasins** are encoded by the ail gene families of each of these

species, as described in Leong et al. (1991) Infect. Immun. 59:3424-3433, the disclosure of which is incorporated herein by reference.

SUMMARY:

BSUM(22)

In addition to **invasins**, a suitable binding moiety may be, for example, a mono- or **polyclonal antibody** or fragment thereof, an IgA **antibody** or fragment thereof, a viral capsid, a capsid of adenovirus, cholera toxin B subunit, transferrin or a fragment thereof, lactoferrin or a fragment thereof, vitamin D, EGF or a fragment thereof, pseudomonas exotoxin, diphtheria toxin, and the like.

SUMMARY:

BSUM(24)

Particularly preferred binding moieties will contain the tripeptide arginine-glycine-aspartic acid (RGD) or the pentapeptide glutamic acid-isoleucine-leucine-aspartic acid-valine (EILDV) within their binding recognition site. The RGD tripeptide is widely conserved among many adhesive proteins present in extracellular matrices as well as being part of at least most **invasin** proteins. The RGD peptide may be utilized by itself and bound to the drug carrier particle, as described in more detail hereinbelow, or it may be obtained or synthesized as part of a larger oligopeptide which is bound to the drug carrier particle. RGD peptide is commercially available from GIBCO BRL Life Technologies, Inc. (Gaithersburg, Md.) and as Peptide-2000.TM. from Telios. Additional preferred binding moieties are the peptides arginine-glycine-aspartic acid-valine (RGDV), arginine-glycine-aspartic acid-serine (RGDS), arginine-glycine-aspartic acid-phenylalanine (RGDF), and glycine-arginine-glycine-aspartic acid-threonine-proline (GRGDTP).

SUMMARY:

BSUM(25)

It will be appreciated that the binding moiety may comprise a variety of other molecular structures, including **antibodies**, lectins, nucleic acids, and other receptor ligands, and fragments thereof. Once a desired target molecule is known, such as the integrins identified above, it will be possible to prepare or synthesize other molecules which are capable of binding the target with the requisite affinity or avidity. For example, **antibodies**, including both **polyclonal** and **monoclonal antibodies**, may be raised against the integrin or other target molecule using conventional techniques, as described in Harlow and Lane, eds., **Antibodies: A Laboratory Manual**, Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y. (1988), the disclosure of which is incorporated herein by reference.

CLAIMS:

CLMS (4)

4. A composition comprising a matrix carrier particle composed of a material which resists proteolytic degradation and which is sufficiently small to be absorbed by a mammalian enterocyte, attached to a binding moiety selected from the group consisting of oligopeptides containing the

Ipab Shizelle (invasin)

sequence RGD, **invasin** molecules or fragments thereof, EGF or fragments thereof, and **antibodies** or fragments thereof, which bind specifically to a target molecule present on the surface of a mammalian enterocyte, the target molecule being an endocytosis- or phagocytosis-promoting receptor.

CLAIMS:

CLMS (10)

10. A composition as in claim 1, wherein the binding moiety comprises an **invasin** molecule or a fragment thereof.

CLAIMS:

CLMS (12)

12. A composition as in claim 1, wherein the binding moiety comprises an **antibody** or a fragment thereof.

CLAIMS:

CLMS (30)

30. A composition as in claim 19, wherein the binding moiety comprises an **invasin** molecule or a fragment thereof.

CLAIMS:

CLMS (32)

32. A composition as in claim 19, wherein the binding moiety comprises an **antibody** or a fragment thereof.

US PAT NO: 5,310,654 [IMAGE AVAILABLE]

L4: 9 of 9

SUMMARY:

BSUM(20)

Constructs may then be prepared which may be used for introducing invasive capability into an appropriate unicellular microorganism host. Depending upon the purpose for invasiveness, a wide variety of bacterial or eukaryotic microorganism hosts may be employed. The subject method provides for introduction of DNA capability into a mammalian cell where the unicellular microorganism is employed as the vehicle for introduction of the DNA capability into a mammalian cell. For example, a shuttle vector may be provided in the invasive microorganism host which has the capability for replication in the mammalian cell as well as the unicellular microorganism, where the shuttle vector may exist as an episomal element or become integrated into the mammalian cell genome. In this manner, unicellular hosts for cloning may be used directly for the transfer of DNA into a mammalian cell host with high efficiency. Thus, a wide variety of genetic capabilities can be introduced into mammalian hosts, for example, the expression of lymphokines, hormones, enzymes, surface membrane proteins, and the like, such as interferons, interleukins, growth factors, hydrolases, oxidoreductases, receptors, **antibodies**, histocompatibility antigens, etc.

SUMMARY:

BSUM(22)

A third manner in which the invasive organism may be used is as a vehicle for the introduction of molecules, particularly macromolecules, into a mammalian cellular host, either in vitro or in vivo. For example, cytotoxic resistance provided by an enzyme could be transferred into cells or a cytotoxic agent, e.g., aminoglycosides, hybritoxins, etc., non-cytotoxic to the microorganism could be introduced into mammalian cells. Dyes or other contrast agents could be introduced into the cells for visualization of cell features. Labelled **antibodies** could be introduced into the cells to define the location of particular antigens. **Invasin** proteins may be used to introduce particles, such as colloidal particles, liposomes, slowly degrading or slow release particles, cells, or the like, where the particles may include drugs, dyes, nucleic acid, **antibodies**, or other substances which may have physiological activity. The **invasin** proteins may be bound non-diffusibly to the particles, either covalently or non-covalently. The literature has numerous examples of commercially available crosslinking agents for joining proteins to other proteins, sugars, synthetic organic polymers, both addition and condensation, and the like.

SUMMARY:

BSUM(23)

Invasin proteins may also be used to bind mammalian cells to a surface. Thus in cell cultures, cells may be reversibly bound to a surface, isolated or otherwise be manipulated. Other uses will also be apparent.

SUMMARY:

BSUM(32)

The invasive microorganisms may be used to prepare antisera for passive immunization. Thus, γ -globulin could be prepared which has **antibodies** to a broad spectrum of pathogens and for strains of a particular pathogen. The γ -globulin may be isolated and purified from serum by ammonium sulfate precipitation and fractionation according to known techniques. Administration to a mammalian host will generally be in amounts of 50 to 500 mg/kg of host in any physiologically acceptable carrier. Administration will usually be by injection, e.g., intravenously. The modified recipient microorganism may also be used in assays for detecting the presence of **antibodies** to the antigens foreign to the modified microorganism or the antigens themselves. They also may find use in competing with the invasive microorganisms so as to be useful for therapy.

SUMMARY:

BSUM(34)

Sequences encoding all or a portion of the **invasin** genes may be used for diagnosing pathogenicity or virulence. Two fragments of interest from the ail locus are 0.9 kbp AvaI - ClaI fragment from the plasmid pVM103 and a 1.2 kb ClaI - AvaI fragment from the same plasmid or fragments thereof of at least about 50 bp, preferably at least about 100 bp or extensions

thereof including the entire ail coding region or locus. In conjunction with the ail probes, a probe referred to as Inv-Ent may be employed, which is a 3.6 kb ClaI fragment obtained from pVM101, or 50 bp fragment thereof, preferably at least a 100 bp fragment thereof. The 3.6 kb fragment comprises most of the inv gene from *Y. enterocolitica* in addition to adjacent sequences. Alternatively, a probe referred to as Inv-PSTB may be employed which is a 2.4 kb ClaI-XhoI fragment obtained from pRI203. Isberg et al., Cell 50:769-778 (1987). Of particular interest is the use of ail specific sequences for detecting pathogenicity. In pathogenic strains multiple copies of sequences having homology to AIL-B are frequently observed. With the Inv probes, a size pattern is observed when the microorganisms DNA is cleaved with EcoRV. These strains may be divided into types I, II, I/II, III, IV and V by the size of fragments observed. This restriction enzyme cuts once within the Inv-Ent probe, but does not cut within the AIL-B or C probes. The various types are defined in the Experimental section where, types I and I/II were found to be pathogenic, while the remaining types were non-pathogenic, with a strong correlation.

DETDESC:

DETD(86)

The above results demonstrate that *Yersinia* have a common invasive gene which is homologous in a plurality of species. That this gene, inv, as well as a second gene, ail, may be readily transferred to a non-invasive microorganism host to provide for invasion by such microorganism into mammalian cells. Furthermore, DNA from the genes may be used for an in vitro assay for determining pathogenicity of *Yersinia* species. The invasive genes find further use in identifying strains, evaluating levels of pathogenicity and relationships between pathogenicity and **invasin** genes.

DETDESC:

DETD(87)

The mammalian cells are able to endocytose the entire microbial cell based on the presence of a particular structure encoded on the surface membrane of the microorganism. The invasive phenotype can be used for diverse purposes, such as the introduction of exogenous DNA or other molecules into mammalian host, induction of an immune response to one or a plurality of antigens associated with pathogens, so as to be useful as vaccines, for production of antiserum having a spectrum of **antibodies** to a spectrum of pathogens, and for the production of proteins which may be used to inhibit invasion of pathogens in mammalian host cells.

ds

Set	Items	Description
S1	85477	R1-R5
S2	923	E2-E20
S3	328	E3-E9
S4	42	"INTIMINS"
S5	86565	S1-S4
S6	1456	INTIMIN? OR INVASIN? OR INTIMIN(N)LIKE OR INTIMIN-LIKE?
S7	86793	S5 OR S6
S8	24031	S7 AND (MONOCLONAL? OR POLYCLONAL? OR ANTIBOD? OR ANTISER? OR IMMUNOGLOB?)
S9	6331	S8/1996:1998
S10	17700	S8 NOT S9
S11	50	TARGET - S10
S12	31721	HAFNIA? OR CITROBACTER? OR YERSINA? OR EHEC? OR EPEC?
S13	1	S11 AND S12
S14	1	TARGET - S13
S15	982193	COLI OR ESCHERICHIA?
S16	1	S11 AND S15
S17	1	TARGET - S16
S18	225	AU=NYSTROM ? AND (EHEC OR COLI)
S19	80	RD (unique items)
S20	1006	S10 AND S15
S21	972	RD (unique items)
S22	50	TARGET - S21
S23	9725	O157?
S24	23	S20 AND S23
S25	16	RD (unique items)

?t s25/9/7 11 12

25/9/7 (Item 4 from file: 73)

DIALOG(R) File 73:EMBASE

(c) 1998 Elsevier Science B.V. All rts. reserv.

8934636 EMBASE No: 93238377

Antigenic cross-reactions between Escherichia coli O157, Vibrio cholerae O1 (Inaba) and group N salmonella

Chart H.; Cheasty T.; Georgiou T.; Rowe B.

Laboratory of Enteric Pathogens, Central Public Health Laboratory, 61 Colindale Avenue, Colindale, London NW9 5HT United Kingdom

SERODIAGNOSIS IMMUNOTHER. INFECT. DIS. (United Kingdom) , 1993, 5/2 (81-84)

CODEN: SIIDE ISSN: 0888-0786

LANGUAGES: English SUMMARY LANGUAGES: English

SUBFILES: 004; 026; 028

Lipopolysaccharide antigen- antibody cross-reactions between **Escherichia coli O157** and other members of the Enterobacteriaceae were examined. Using serotyping schemes established in the Laboratory of Enteric Pathogens (LEP), cross-reactions were demonstrated between **E. coli O157** , **Vibrio cholerae O1- Inaba** and group N (O = 30) salmonella. SDS-PAGE and immunoblotting showed that the lipopolysaccharide (LPS) of **E. coli O157** contained epitopes shared with LPS expressed by group N salmonella. These cross-reactions were also detected using sera from patients with haemolytic uraemic syndrome (HUS) caused by **E. coli O157 :H7**. Rabbit **antibodies** , prepared to the LPS of **V. cholerae O1-Inaba** reacted with the LPSs of both **E. coli O157** and **V. cholerae O1-Inaba**, whilst rabbit **antisera** prepared to **E. coli O157** did not react with the LPS of **V. cholerae O1-Inaba**. **Antibodies** in sera from patients with HUS, which reacted with the LPS of **E. coli O157** , did not react with the LPS from **V. cholerae O1-Inaba**. We concluded from our study that cross-reactions between **E. coli O157** and other bacterial species are rare; and that patients infected with bacteria known to share epitopes with **E. coli O157** are unlikely to give false positive results when their sera were tested for **E. coli O157** serology.

EMTAGS:

Bacterium 0762; Diagnosis 0140; Nonhuman 0777; Article 0060

DRUG DESCRIPTORS:

*bacterial antigen

MEDICAL DESCRIPTORS:

***escherichia coli** ; *vibrio cholerae; *salmonella; *hemolytic uremic syndrome--diagnosis--di cross reaction; nonhuman; article

CAS REGISTRY NO.: 68583-22-2

25/9/11 (Item 8 from file: 73)

DIALOG(R) File 73:EMBASE

(c) 1998 Elsevier Science B.V. All rts. reserv.

8487472 EMBASE No: 92163681

Serological cross-reactions between Escherichia coli O157 and other species of the genus Escherichia

Rice E.W.; Sowers E.G.; Johnson C.H.; Dunnigan M.E.; Strockbine N.A.; Edberg S.C.

U.S. Environmental Protection Agency, Cincinnati, OH 45268 USA

J. CLIN. MICROBIOL. (USA) , 1992, 30/5 (1315-1316)

CODEN: JCMID ISSN: 0095-1137

LANGUAGES: English SUMMARY LANGUAGES: English

SUBFILES: 004

The antigenic relatedness of **Escherichia coli O157** and four sorbitol- negative species of the genus **Escherichia** was examined. Isolates of **Escherichia hermannii**, **E. fergusonii**, **E. vulneris**, and **E. blattae** were tested in the tube agglutination assay by using **polyclonal antisera** and in the slide agglutination assay by using latex reagents. Only four isolates (17%) of **E. hermannii** exhibited serological cross-reactivity.

EMTAGS:

Bacterium 0762; Immunological procedures 0102; Diagnosis 0140; Apparatus, equipment and supplies 0510; Nonhuman 0777; Controlled study 0197; Priority journal 0007; Note 0063

DRUG DESCRIPTORS:

*cross reacting antigen--endogenous compound--ec; *bacterial antigen --endogenous compound--ec sorbitol

MEDICAL DESCRIPTORS:

***escherichia coli** ; *species difference; *cross reaction latex agglutination test; serology; bacterium isolation; agglutination test ; tube; nonhuman; controlled study; priority journal; note

CAS REGISTRY NO.: 68583-22-2; 50-70-4

25/9/12 (Item 9 from file: 73)

DIALOG(R) File 73:EMBASE

(c) 1998 Elsevier Science B.V. All rts. reserv.

8136806 EMBASE No: 91166077

Enzyme-linked immunosorbent assay for products of the 60-megadalton plasmid of Escherichia coli serotype O157:H7

Toth I.; Barrett T.J.; Cohen M.L.; Rumschlag H.S.; Green J.H.; Wachsmuth I.K.

Division of Bacterial and Mycotic Diseases, Center for Infectious Diseases, Centers for Disease Control, Atlanta, GA 30333 USA

J. CLIN. MICROBIOL. (USA) , 1991, 29/5 (1016-1019)

CODEN: JCMID ISSN: 0095-1137

LANGUAGES: English

SUBFILES: 004

Eighty strains of pathogenic **Escherichia coli** , representing each of the major diarrheal disease-causing groups, were examined by direct enzyme-linked immunosorbent assay (ELISA) for the presence of proteins

associated with a 60-MDa plasmid from *E. coli* serotype O157:H7. Antiserum specific for plasmid-encoded proteins was prepared by immunizing a rabbit with a wild-type *E. coli* O157:H7 strain (strain 7785) and absorbing the serum with a plasmid-cured derivative (strain 2-45). Use of this antiserum in Western immunoblot analysis detected two proteins of 82 and 92 kDa in strain 7785 but not in strain 2-45. All 16 wild-type *E. coli* O157:H7 strains and all 10 Shiga-like toxin (SLT)-producing *E. coli* strains of serotypes other than O157 were ELISA positive. Thirteen of 14 enterotoxigenic and all of 24 enteroinvasive *E. coli* strains were ELISA negative, as were all of 16 *E. coli* strains isolated from healthy persons. Of 16 traditional enteropathogenic *E. coli* (EPEC) serotypes, 10 were ELISA positive, including 10 of 12 strains carrying the EPEC adherence factor gene. Absorption of the serum with an EPEC adherence factor-positive EPEC eliminated EPEC reactivity. This study demonstrates that two plasmid-mediated proteins are common to *E. coli* O157:H7 strains and to SLT-producing strains of other serotypes. Detection of these proteins by ELISA provides a sensitive and specific screening test for identifying SLT-producing *E. coli* of both O157 and non-O157 serotypes. Identification of the cross-reactive proteins found in EPEC could provide the basis for a single assay to detect both EPEC and SLT-producing *E. coli*.

EMTAGS:

Heredity 0137; Immunological procedures 0102; Etiology 0135; Therapy 0160; Prevention 0165; Genetic engineering 0108; Mammal 0738; Human 0888; Priority journal 0007; Article 0060; Bacterium 0762

DRUG DESCRIPTORS:

*bacterial protein

MEDICAL DESCRIPTORS:

*serotype; *plasmid; *enzyme linked immunosorbent assay; *diarrhea

--etiology--et; **Escherichia coli*

antibody production; immunization; immunoblotting; staining; hybridization; cross reaction; gene sequence; bacterium adherence; human; priority journal; article; polyacrylamide gel electrophoresis

CAS REGISTRY NO.: 68583-22-2

?t s25/3,kwic/16

25/3,KWIC/16 (Item 1 from file: 444)

DIALOG(R)File 444:New England Journal of Med.

(c) 1998 Mass. Med. Soc. All rts. reserv.

00108965

Copyright 1991 by the Massachusetts Medical Society

Medical Progress: Bacterial And Protozoal Gastroenteritis (Review Article)

Guerrant, Richard L.; Bobak, David A.

The New England Journal of Medicine

Aug 1, 1991; 325 (5),pp 327-340

LINE COUNT: 00741

WORD COUNT: 10238

TEXT

...identified bacterial pathogens, such as *Helicobacter pylori*, and a still growing range of types of *Escherichia coli* to protozoal, algal, and fungal enteric pathogens. This overview will provide an update and a...

...relatively low, according to studies in human volunteers. An infectious dose of *Vibrio cholerae*, *Esch. coli*, or *salmonella* usually requires the ingestion of 10(sup 5) to 10(sup 8) organisms...Although there have been reports of shigella, salmonella, aeromonas, cryptosporidium, and other infections, enterotoxigenic *Esch. coli* that produces either the heat-labile toxin, the heat-stable toxin, or both is consistently... proctocolitis. Diarrhea with blood, especially without fecal leukocytes, suggests enterohemorrhagic (Shiga-like-toxin producing) *Esch. coli* O157 or amebiasis (in which leukocytes are destroyed by the parasite). Ingestion of inadequately cooked seafood...

...of giardiasis or cryptosporidiosis. Travel to tropical areas increases the chance of having enterotoxigenic *Esch. coli* infection, as well as viral (Norwalk-like or rotaviral), parasitic (giardia, entamoeba, strongyloides, or cryptosporidium...

...or infection with *Staph. aureus*, *B. cereus* (incubation periods, <6 hr), *Cl. perfringens*, enterotoxigenic *Esch. coli* (ETEC), vibrio, salmonella, campylobacter, shigella, or enteroinvasive *Esch. coli* (EIEC). Consider saving *Esch. coli* samples for serotyping and testing for heat-labile toxin (LT), heat-stable toxin (ST), invasiveness...tests for enterocytozoan are not yet available, serologic surveys suggest an association of *Enceph. cuniculi* antibody with tropical areas (Ref. 132). Isolated cases have improved after treatment with pyrimethamine, metronidazole, or...

...and electrolytes (Ref. 145-147). Active immunity, as well as passive protection by breast-milk antibody, lactoferrin, lysozyme, antibody, and other factors help prevent many enteric infections (Ref. 148). Finally, the protective effect of...

...important as its species in defining it as a pathogen. For example, the versatile *Esch. coli* can be normal, predominant aerobic flora or can express a range of virulence traits from...

...watery, noninflammatory diarrhea to shigella-like invasiveness, often encoded on transferrable plasmids or phage. *Esch. coli* and some other enteric organisms can produce one or more of three types of enterotoxins...

...*Cl. perfringens* type A, *Staph. aureus*, *Bacillus cereus*, *B. fragilis*, and two recently described *Esch. coli* products cause fluid secretion in animal models or electrogenic responses in Ussing chambers (Ref. 169...

...include shiga toxin and the shiga-like toxins (or vero cytotoxins) produced by "enterohemorrhagic" *Esch. coli* that bind to globotriaosylceramide and cleave an adenosine from host-cell ribosomal RNA to halt...toxin in causing disease. Two-to-seven-nanometer surface fibrillae or fimbriae of enterotoxigenic *Esch. coli* (colonization-factor antigens I to V) are critical to the capacity of the organism to...

...bowel, (Ref. 139,185-187) as well as in the initial colonization of enterohemorrhagic *Esch. coli* O157 and "enteropathogenic" *Esch. coli* (Ref. 188,189). Enteropathogenic *Esch. coli* also exhibits localized attaching and effacing adherence and F-actin polymerization in brush-border and cultured HEP-2 cells (Ref. 190-194). *Esch. coli* with a different aggregative adherence has been associated with persistent diarrhea in studies in India and Brazil, (Ref. 195-197) and diffusely adhering *Esch. coli*, which produces a mannose-resistant hemagglutinin (Ref. 198) may also be associated with diarrhea (Ref...

...glycolipids), cell invasion may involve attachment to transmembrane glycoproteins such as integrin bound by yersinia *invasin* (Ref. 200). Shigella and enteroinvasive *Esch. coli* plasmids encode a series of *invasin* and adhesin proteins (ipa A to D) that are regulated by chromosomal codons such as...

...upper small bowel from the action of an enterotoxin (as with cholera or enterotoxigenic *Esch. coli* diarrhea) or other process that specifically alters the absorptive function of the villus tip (e.g., agents such as enteropathogenic *Esch. coli*, cryptosporidium, giardia, rotaviruses, or Norwalk-like viruses). In contrast, inflammatory dysentery usually arises in the...

...homosexual patients or those with AIDS. Specific clues may suggest inflammatory diarrhea, yersinia, enterohemorrhagic *Esch. coli*, *Ent. histolytica*, vibrio, *Cl. difficile*, giardia, cryptosporidium, enterotoxigenic *Esch. coli*, food poisoning, or sexually transmitted or other pathogens (Fig. 1). In immunocompromised patients endoscopy and...An effective, absorbable antimicrobial agent can reduce the duration of

symptoms in shigella, enterotoxigenic *Esch. coli*, vibrio, and sometimes *Camp. jejuni* infections. The increasing resistance of enteric pathogens to commonly used...

...the range of available effective agents (Ref. 219). For example, 44 percent of enterotoxigenic *Esch. coli* and 79 percent of shigella isolated from U.S. troops in Saudi Arabia in 1990...

...antigen is leading to new developments in vaccines against typhoid fever, cholera, and enterotoxigenic *Esch. coli*, shigella, and other enteric infections (Ref. 187,227,228...

...travel brings the affluent into increasing contact with common enteric infections such as enterotoxigenic *Esch. coli* that plague children in tropical developing countries around the world. Similarly, institutional care in day...

...advances in our understanding of the traits of microbial virulence (such as adhesins, toxins, and **invasins**) and host responses have reached the molecular level and now open exciting biochemical, immunologic, and...

CITED REFERENCES

...secretion and impaired villous function induced by colonization of the small intestine by nontoxigenic colonizing *Escherichia coli*. *Infect Immun* 1990; 58:1337-43.

49. Black RE. Pathogens that cause travelers' diarrhea in...*Annu Rev Microbiol* 1983; 37:603-22.

82. Kelsall BL, Ravdin JI. Degradation of human immunoglobulin by *Entamoeba histolytica*. In: Program and abstracts of the 39th annual meeting of the American...Linggood MA. Observations of the pathogenic properties of the K88, Hly, and Ent plasmids of *Escherichia coli* with particular reference to porcine diarrhoea. *J Med Microbiol* 1971; 4:467-85.

139. Evans...

...Evans DJ Jr, Chase DG, Gorbach SL. Plasmid-controlled colonization factor associated with virulence in *Escherichia coli* enterotoxigenic for humans. *Infect Immun* 1975; 12:656-67.

140. Rutter JM, Burrows MR, Sellwood R, Gibbons RA. A genetic basis for resistance to enteric disease caused by *E. coli*. *Nature* 1975; 257:135-6.

141. Mobassaleh M, Donohue-Rolfe A, Jacewicz M, Grand RJ...BEC, Pickett CL, Twiddy EM, et al Production of type II heat-labile enterotoxin by *Escherichia coli* isolated from food and human feces. *Infect Immun* 1986; 54:587-9.

160. Hughes JM...

...B, Guerrant RL. Role of cyclic GMP in the action of heat-stable enterotoxins of *Escherichia coli*. *Nature* 1978; 271:755-6.

161. Field M, Graf LH Jr, Laird WJ, Smith PL. Heat stable enterotoxin of *Escherichia coli*: in vitro effects on guanylate cyclase activity, cyclic GMP concentration, and ion transport in small...

...B, Robertson DC, Murad F. Activation of intestinal guanylate cyclase by heat-stable enterotoxin of *Escherichia coli*: studies of tissue specificity, potential receptors, and intermediates. *J Infect Dis* 1980; 142:220-8.

163. Kennedy DJ, Greenberg RN, Dunn JA, Abernathy R, Ryerse JS, Guerrant RL. Effects of *Escherichia coli* heat-stable enterotoxin STb on intestines of mice, rats, rabbits, and piglets. *Infect Immun* 1984...

...Guerrant RL. In vivo and in vitro effects of a novel enterotoxin, STb, produced by *Escherichia coli*. *J Infect Dis* 1986; 153:893-901. Erratum, *J Infect Dis* 1986; 154:1053.]

165...

...freundii produces an 18-amino-acid heat-stable enterotoxin identical to the 18-amino-acid *Escherichia coli* heat-stable enterotoxin (ST1a).

- Infect Immun 1989; 57:649-52.
169. Lysterly DM, Krivan...
- ...Kay BA, Russell RG, Maneval DR Jr, Levine MM. Enterotoxin and cytotoxin production by enteroinvasive *Escherichia coli*. Infect Immun 1990; 58:3717-23.
173. Savarino SJ, Fasano A, Robertson DC, Levine MM. Enterotoxigenic *Escherichia coli* elaborate a heat-stable enterotoxin demonstrable in an in vitro rabbit intestinal model. J Clin...
- ...Blackwell Scientific (in press).
186. Satterwhite TK, Evans DG, DuPont HL, Evans DJ. Role of *Escherichia coli* colonisation factor antigen in acute diarrhoea. Lancet 1978; 2:181-4.
187. Levine MM, Kaper...
- ...Heesemann J, Laufs R, O'Brien AD, Tacket CO, Levine MM. A plasmid of enterohemorrhagic *Escherichia coli* O157:H7 is required for expression of a new ...Baldini MA, Kaper JB, Levine MM, Candy DCA, Moon HW. Plasmid-mediated adhesin in enteropathogenic *Escherichia coli*. J Pediatr Gastroenterol Nutr 1983; 2:534-8.
190. Rothbaum R, McAdams AJ, Giannella R, Partin JC. A clinicopathologic study of enterocyte-adherent *Escherichia coli*: a cause of protracted diarrhea in infants. Gastroenterology 1982; 83:441-54.
191. Levine MM, Bergquist EJ, Nalin DR, et al *Escherichia coli* strains that cause diarrhea but do not produce heat-labile or heat-stable enterotoxins and...
- ...Cravioto A, Gross RJ, Scotland S, Rowe B. An adhesive factor found in strains of *Escherichia coli* belonging to the traditional infantile enteropathogenic serotypes. Curr Microbiol 1979; 3:95-9.
193. Nataro...
- ...JB, Robins-Browne R, Prado V, Vial P, Levine MM. Patterns of adherence of diarrheagenic *Escherichia coli* to HEp-2 cells. Pediatr Infect Dis J 1987; 6:829-31.
194. Knutton S...
- ...adhesion to tissue culture cells: basis of a new diagnostic test for enteropathogenic and enterohemorrhagic *Escherichia coli*. Infect Immun 1989; 57:1290-8.
195. Vial PA, Robins-Browne R, Lior H, et al Characterization of enteroadherent-aggregative *Escherichia coli*, a putative agent of diarrheal disease. J Infect Dis 1988; 158:70-9.
196. Bhan MK, Raj P, Levine MM, et al Enterotoxigenic *Escherichia coli* associated with persistent diarrhea in a cohort of rural children in India. J Infect Dis...
- ...GD, Lima AM, Wanke CA, Kaper JB, Levine MM, Guerrant RL. HEp2 cell-adherent *E. coli*: potential causes of persistent diarrhea of multiple genotypes and different adherence phenotypes. Clin Res 1991...
- ...Moseley SL. Molecular characterization of a fimbrial adhesin, F1845, mediating diffuse adherence of diarrhea-associated *Escherichia coli* to HEp-2 cells. J Bacteriol 1989; 171:4281-9.
199. Giron JA, Jones T, Millan-Velasco F, et al Diffuse-adhering *Escherichia coli* (DAEC) as a putative cause of diarrhea in Mayan children in Mexico. J Infect Dis...
- ...252:934-8.
201. Sansonetti PJ, Hale TL, Oakes EV. Genetics of virulence in enteroinvasive *Escherichia coli*. In: Microbiology. Washington, D.C.: American Society for Microbiology, 1985:74-7.
202. Maurelli AT...
- ...AAM, Khin-Maung U, Guerrant RL. Physiologic basis for oral rehydration therapy of enterotoxigenic *E. coli* and rotaviral diarrhea. In:

Guerrant RL, de Souza MA, Nations MK, eds. At the edge...
?logoff hold

Passive protective effect of chicken egg yolk immunoglobulin against experimental enterotoxigenic Escherichia coli infection in neonatal piglets

Yokoyama H.; Peralta R.C.; Diaz R.; Sendo S.; Ikemori Y.; Kodama Y.

Immunology Research Institute in Gifu, Minamiyama, Sano, Gifu City 501-11 Japan

INFECT. IMMUN. (USA) , 1992, 60/3 (998-1007)

CODEN: INFIB ISSN: 0019-9567

LANGUAGES: English SUMMARY LANGUAGES: English

SUBFILES: 004; 026

Passive protection of neonatal piglets against fatal enteric colibacillosis was achieved with powder preparations of specific antibodies against K88, K99, and 987P fimbrial adhesins of enterotoxigenic Escherichia coli. The antibody powders were obtained by spray drying the water-soluble protein fraction of egg yolks from immunized hens after the lipid components were precipitated with an aqueous dispersion of acrylic resins (Eudragit L30D-55; Rohm pharma). The anti-K88, -K99, and -987P antibody preparations reacted specifically against the corresponding fimbrial antigens in an enzyme-linked immunosorbent assay. The orally administered antibodies protected in a dose-dependent fashion against infection with each of the three homologous strains of E. coli in passive immunization trials with a colostrum-deprived piglet model of enterotoxigenic E. coli diarrhea. Scanning electron microscopy revealed adherence of enterotoxigenic E. coli in intestinal epithelial surfaces of control piglets, whereas in treated piglets treated with high-titer **antibodies**, a resistance to bacterial adhesion was observed. An enzyme immunoassay with avidin-biotin complex demonstrated specific local **antibody** activity in target areas of the small intestines. In vitro, E. coli K88+, K99+, and 987P+ strains adhered equally to porcine duodenal and ileal epithelial cells but failed to do so in the presence of homologous anti-fimbrial **antibodies**. Absorption of egg yolk **antibodies** with fimbrial immunosorbent removed the anti-fimbrial **antibody** fraction and reduced significantly the protective nature of the **antibody** preparation in a passive immunization experiment, suggesting that anti-fimbrial **antibodies** were the active components.

EMTAGS:

Bacterium 0762; Infectious diseases 0310; Diagnosis 0140; Therapy 0160; Etiology 0135; Prevention 0165; Swine 0729; Mammal 0738; Digestive system 0935; Small intestine 0941; Bird 0703; Chicken 0709; Nonhuman 0777; Animal experiment 0112; Controlled study 0197; Animal tissue, cells or cell components 0105; Newborn 0013; Infant 0014; Child 0022; Oral and intragastric drug administration 0181; Priority journal 0007; Article 0060

DRUG DESCRIPTORS:

*immunoglobulin--drug dose--do; *immunoglobulin--drug therapy--dt; *immunoglobulin--endogenous compound--ec
adhesin--endogenous compound--ec

MEDICAL DESCRIPTORS:

*escherichia coli; *experimental infection--diagnosis--di; *experimental infection--drug therapy--dt; *experimental infection--etiology--et; *passive immunization
swine; bacterium adherence; egg yolk; fimbria; diarrhea--drug therapy--dt; diarrhea--etiology--et; intestine epithelium cell; duodenum; ileum; colostrum; dose response; chicken; nonhuman; animal experiment; controlled study; animal cell; newborn; oral drug administration; priority journal; article

EMCLAS DRUG CODES:

03700000000

CAS REGISTRY NO.: 68583-22-2; 9007-83-4

22/9/24 (Item 24 from file: 73)

DIALOG(R) File 73:EMBASE

(c) 1998 Elsevier Science B.V. All rts. reserv.

8934636 EMBASE No: 93238377

Antigenic cross-reactions between Escherichia coli O157, Vibrio cholerae

01 (Inaba) and group N salmonella

Chart H.; Cheasty T.; Georgiou T.; Rowe B.

Laboratory of Enteric Pathogens, Central Public Health Laboratory, 61 Colindale Avenue, Colindale, London NW9 5HT United Kingdom

SERODIAGNOSIS IMMUNOTHER. INFECT. DIS. (United Kingdom) , 1993, 5/2 (81-84)

CODEN: SIIDE ISSN: 0888-0786

LANGUAGES: English SUMMARY LANGUAGES: English

SUBFILES: 004; 026; 028

Lipopolysaccharide antigen-antibody cross-reactions between *Escherichia coli* 0157 and other members of the Enterobacteriaceae were examined. Using serotyping schemes established in the Laboratory of Enteric Pathogens (LEP), cross-reactions were demonstrated between *E. coli* 0157, *Vibrio cholerae* 01- Inaba and group N (O = 30) salmonella. SDS-PAGE and immunoblotting showed that the lipopolysaccharide (LPS) of *E. coli* 0157 contained epitopes shared with LPS expressed by group N salmonella. These cross-reactions were also detected using sera from patients with haemolytic uraemic syndrome (HUS) caused by *E. coli* 0157:H7. Rabbit **antibodies**, prepared to the LPS of *V. cholerae* 01-Inaba reacted with the LPSs of both *E. coli* 0157 and *V. cholerae* 01-Inaba, whilst rabbit **antisera** prepared to *E. coli* 0157 did not react with the LPS of *V. cholerae* 01-Inaba.

Antibodies in sera from patients with HUS, which reacted with the LPS of *E. coli* 0157, did not react with the LPS from *V. cholerae* 01-Inaba. We concluded from our study that cross-reactions between *E. coli* 0157 and other bacterial species are rare; and that patients infected with bacteria known to share epitopes with *E. coli* 0157 are unlikely to give false positive results when their sera were tested for *E. coli* 0157 serology.

EMTAGS:

Bacterium 0762; Diagnosis 0140; Nonhuman 0777; Article 0060

DRUG DESCRIPTORS:

*bacterial antigen

MEDICAL DESCRIPTORS:

**escherichia coli*; **vibrio cholerae*; *salmonella; *hemolytic uremic syndrome--diagnosis--di cross reaction; nonhuman; article

CAS REGISTRY NO.: 68583-22-2

22/9/42 (Item 42 from file: 73)

DIALOG(R) File 73:EMBASE

(c) 1998 Elsevier Science B.V. All rts. reserv.

7324859 EMBASE No: 89041160

Serum antibodies to *Escherichia coli* serotype 0157:H7 in patients with hemolytic uremic syndrome

Chart H.; Scotland S.M.; Rowe B.

Division of Enteric Pathogens, Central Public Health Laboratory, London NW9 5HT United Kingdom

J. CLIN. MICROBIOL. (USA) , 1989, 27/2 (285-290)

CODEN: JCMID ISSN: 0095-1137

LANGUAGES: English

SUBFILES: 004; 025; 026; 028; 048

Sera from 13 patients with hemolytic uremic syndrome (HUS) and 8 healthy controls subjects were examined for **antibodies** specific for bacterial antigens of *Escherichia coli* serotype 0157:H7. Bacterial components, including outer membrane proteins (OMPs), lipopolysaccharide (LPS), and flagella, were reacted with sera by sodium dodecyl sulfate-polyacrylamide gel electrophoresis followed by immunoblotting and by enzyme-linked immunosorbent assay. All 13 serum samples from HUS patients contained high-titered **antibodies** of the immunoglobulin M class against 0157 LPS and some OMPs. These same sera reacted weakly with some of the major OMPs, but not the LPS, of non-0157 strains of *E. coli*. Sera from patients did not contain **antibodies** to non-0157 LPS or H7 flagella. The possibility of using *E. coli* serotype 0157 LPS in an enzyme-linked immunosorbent assay for the routine diagnostic testing of sera from HUS patients for evidence

of O157:H7 infection is discussed.

EMTAGS:

Bacterium 0762; Blood and hemopoietic system 0927; Urinary tract 0950;
Enzyme 0990; Preschool child 0015; School child 0016; Adult 0018; Human
0888; Infectious diseases 0310; Immunological procedures 0102; Controlled
study 0197; Clinical article 0152; Male 0041; Female 0042; Priority journal
0007

MEDICAL DESCRIPTORS:

*escherichia coli; *antibody detection; *serotype; *hemolytic uremic
syndrome
outer membrane protein; flagellum; polyacrylamide gel electrophoresis;
immunoblotting; bacterium lipopolysaccharide; antibody titer; enzyme linked
immunosorbent assay; immunoglobulin m; preschool child; school child;
adult

CAS REGISTRY NO.: 68583-22-2; 9007-85-6

?t s22/3/4

22/3/4 (Item 4 from file: 149)

DIALOG(R)File 149:IAC(SM)Health&Wellness DB(SM)

(c) 1998 Info Access Co. All rts. reserv.

01315089 SUPPLIER NUMBER: 10844723 (USE FORMAT 7 OR 9 FOR FULL TEXT)

**Discrimination between intracellular uptake and surface adhesion of
bacterial pathogens.**

Isberg, Ralph R.

Science, v252, n5008, p934(5)

May 17,

1991

PUBLICATION FORMAT: Magazine/Journal ISSN: 0036-8075 LANGUAGE: English

RECORD TYPE: Fulltext TARGET AUDIENCE: Academic

WORD COUNT: 5506 LINE COUNT: 00470

?t s19/6/all